At Illumina, their goal is to apply innovative technologies and revolutionary assays to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. These studies will help make the realization of personalized medicine possible. With such rapid advances in technology taking place, it is mission critical to have solutions that are not only innovative, but flexible, scalable, and complete with industry-leading support and service. As a global company that places high value on collaborative interactions, rapid delivery of solutions, and prioritizing the needs of its customers, they strive to meet this challenge. Illumina's innovative, array-based solutions for DNA, RNA, and protein analysis serve as tools for disease research, drug development, and the development of molecular tests in the clinic.

Research Grants 79 show all


$14.1M
2012

$14M
2014

$13.9M
2015

$312.2K
2016

$231.2K
2017

Patents 3,231show all

  • 808
    C12Q - Measuring or testing processes involving enzymes, nucleic acids or microorganisms
  • 325
    G01N - Investigating or analysing materials by determining their chemical or physical properties
  • 284
    B01J - Chemical or physical processes, e.g. catalysis or colloid chemistry
  • 220
    B01L - Chemical or physical laboratory apparatus for general use
  • 219
    C40B - Combinatorial chemistry
  • 170
    C12N - Microorganisms or enzymes
  • 104
    G16B - Bioinformatics, i.e. information and communication technology [ict] specially adapted for genetic or protein-related data processing in computational molecular biology
  • 101
    C07H - Sugars
  • 90
    G02B - Optical elements, systems, or apparatus
  • 77
    B82Y - Specific uses or applications of nanostructures

Clinical Trials 13show all

3N/A1Phase 3

SEC Filings show all


214
8-K

59
10-Q

19
10-K

1
S-1

Contact Information

5200 Illumina Way
San Diego, CA 92122
United States

Overview

Total FundingEmployeesLast Funding DateStatus
5001-10000Ipo